Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

SALT LAKE CITY, Oct. 14, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (“SMSNA”). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation (“DV”) study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting.  The presentations will take place virtually on November 9, 2020

Read More

Mount Prospect Historical Society cancels annual Holiday Housewalk

The Mount Prospect Historical Society board of directors has chosen to cancel its 33rd annual Holiday Housewalk for December 2020 due to the global COVID-19 pandemic.

“We couldn’t imagine homeowners wanting to open their homes to the public under the current conditions, and we also couldn’t foresee many people choosing to tour the homes this year,” said Jean Murphy, Housewalk co-chairman.

        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

 

“But it will be back. The Housewalk is the society’s largest fundraiser of the year,” Murphy said. “Its proceeds support the many educational endeavors of the society and help to pay for upkeep on our museum campus.”

“We have decided to miniaturize the annual event and offer the ‘2020 Holiday Housewalk: Dollhouse Edition,’ showcasing some of the dollhouses from the Historical Society collection and community in a virtual exhibit,” said Emily Dattilo, museum director. “Stay tuned for more information.”

Those interested can connect on Facebook, www.facebook.com/mphistory, or visit www.mtphist.org,

Read More

CJ Extra: Helping Hands Humane Society’s annual fundraiser supports, helps care for animals – News – The Topeka Capital-Journal

Most events have changed in format this year because of COVID-19, and the same is true for Bone Appetit, a fundraiser that helps defray the costs of Helping Hands Humane Society while celebrating the human-animal connection.

Grace Clinton, director of business development and special events at Helping Hands Humane Society, answered questions about this year’s event.

Could you share Bone Appetit’s history along with its purpose and goals?

Since 2001, Bone Appétit has been our annual dinner and gala fundraiser to help the homeless animals in the Shawnee County community and the greater area of northeast Kansas. This essential fundraiser helps our organization care for over 6,000 animals who come through HHHS’s doors each year, and allows us to celebrate the human-animal bond with our supporters. These funds are vital to continuing our lifesaving mission.

When does this year’s event take place? How has COVID-19 changed this year’s event?

This

Read More

Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.


DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020


“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.


DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.


“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr.

Read More

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

JERUSALEM, Oct. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting preclinical data for DSP107, a second generation CD47x41BB targeting compound for the treatment of solid tumors and hematological malignancies, has been accepted for an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020.

“The ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD47x41BB clinical stage drug candidate,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “We look forward to advancing the clinical development of this novel therapy.”

The following abstract will be posted on the ASH website on November 5, 2020, at 9:00 a.m. ET:

Title: DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition

Read More

Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery’s Annual Meeting (ASDS)

DUBLIN, Oct. 9, 2020 /PRNewswire/ — Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics’ Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured during the American Society for Dermatologic Surgery’s Annual Meeting (ASDS). These data will be highlighted in three posters and two oral presentations during the virtual meeting taking place October 9 – 11, 2020.

Oral Presentations

On Friday, October 9th a presentation titled “Results From a 1000+ Subject Survey Assessing Satisfaction With a Hypothetical 1-Point Improvement on the Validated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) Analysis,” will be given by Sabrina Fabi, M.D., a board-certified dermatologist in California. Dr. Fabi will share results from a study designed to determine if a 1-point improvement in PR-PCSS score is a clinically meaningful outcome and will highlight the

Read More

Castle Biosciences to Present Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

Oral presentations to highlight both commercially available skin cancer prognostic tests

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020.

Presentation details are as follows:

Title: Clinical validation and incorporation of a prognostic 40-gene expression profile test into clinicopathological risk assessment for cutaneous squamous cell carcinoma (cSCC)
Session: Skin Cancer & Reconstruction
Presenter: Sherrif Ibrahim M.D., Ph.D., associate professor, University of Rochester Medical Center
Date: Friday, October 9, 2020
Time: 6:24 p.m. – 6:27 p.m. ET

Title: Cutaneous melanoma prognostic model combining 31-gene expression profile and sentinel lymph node biopsy
Session: Skin Cancer & Reconstruction
Presenter: Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas
Date: Friday, October 9, 2020
Time: 6:30 p.m. –

Read More

Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting

HOUSTON, Oct. 5, 2020 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

The poster presentation titled, “Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial”, will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

————————
Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
————————

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center.

Read More

Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting | News

HOUSTON, Oct. 5, 2020 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

The poster presentation titled, “Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial”, will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

————————
Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
————————

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The

Read More

Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting | Nachricht

HOUSTON, Oct. 5, 2020 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

The poster presentation titled, “Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial”, will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

————————
Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
————————

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The

Read More